Pediatric Dosing and Body Size in Biotherapeutics

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2016 Oct 11

PMID 27721364

Citations 13

Authors

Rong Shi

Hartmut Derendorf

Affiliations

Soon will be listed here.

Abstract

Although pediatric doses for biotherapeutics are often based on patients' body weight (mg/kg) or body surface area (mg/m²), linear body size dose adjustment is highly empirical. Growth and maturity are also important factors that affect the absorption, distribution, metabolism and excretion (ADME) of biologics in pediatrics. The complexity of the factors involved in pediatric pharmacokinetics lends to the reconsideration of body size based dose adjustment. A proper dosing adjustment for pediatrics should also provide less intersubject variability in the pharmacokinetics and/or pharmacodynamics of the product compared with no dose adjustment. Biological proteins and peptides generally share the same pharmacokinetic principle with small molecules, but the underlying mechanism can be very different. Here, pediatric and adult pharmacokinetic parameters are compared and summarized for selected biotherapeutics. The effect of body size on the pediatric pharmacokinetics for these biological products is discussed in the current review.

Citing Articles

Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects.

Mora J, Climent A, Roldan M, Flores M, Varo A, Perez-Jaume S Front Oncol. 2024; 14:1380917.

PMID: 38812778 PMC: 11134175. DOI: 10.3389/fonc.2024.1380917.

Real-world evidence on the dosing and safety of C.E.R.A. in pediatric dialysis patients: findings from the International Pediatric Dialysis Network registries.

Kohlhas L, Studer M, Rutten-Jacobs L, Reigner S, Sander A, Yap H Pediatr Nephrol. 2023; 39(3):807-818.

PMID: 37566114 PMC: 10817843. DOI: 10.1007/s00467-023-05977-z.

Altered Response Pattern following AZD5582 Treatment of SIV-Infected, ART-Suppressed Rhesus Macaque Infants.

Bricker K, Obregon-Perko V, Williams B, Oliver D, Uddin F, Neja M J Virol. 2022; 96(7):e0169921.

PMID: 35293766 PMC: 9006931. DOI: 10.1128/jvi.01699-21.

A population physiologically-based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab.

Chang H, Shakhnovich V, Frymoyer A, Funk R, Becker M, Park K Br J Clin Pharmacol. 2021; 88(1):290-302.

PMID: 34189743 PMC: 8714867. DOI: 10.1111/bcp.14963.

Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim.

Basu S, Lien Y, Vozmediano V, Schlender J, Eissing T, Schmidt S Front Pharmacol. 2020; 11:868.

PMID: 32595502 PMC: 7300301. DOI: 10.3389/fphar.2020.00868.

References

Gale R, Hird M, Colvin B . Management of a premature infant with moderate haemophilia A using recombinant factor VIII. Haemophilia. 1999; 4(6):850-3. DOI: 10.1046/j.1365-2516.1998.00201.x. View

Macdougall I, Gray S, Elston O, Breen C, Jenkins B, Browne J . Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999; 10(11):2392-5. DOI: 10.1681/ASN.V10112392. View

Kovarik J, Kahan B, Rajagopalan P, Bennett W, Mulloy L, Gerbeau C . Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. Transplantation. 1999; 68(9):1288-94. DOI: 10.1097/00007890-199911150-00012. View

Peters A, Henderson B, Lui D . Indexed glomerular filtration rate as a function of age and body size. Clin Sci (Lond). 2000; 98(4):439-44. View

Mortensen H, Lindholm A, Olsen B, Hylleberg B . Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr. 2000; 159(7):483-8. DOI: 10.1007/s004310051315. View

Zeuzem S, Feinman S, Rasenack J, Heathcote E, Lai M, Gane E . Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000; 343(23):1666-72. DOI: 10.1056/NEJM200012073432301. View

Authier F, Danielsen G, Kouach M, Briand G, Chauvet G . Identification of insulin domains important for binding to and degradation by endosomal acidic insulinase. Endocrinology. 2001; 142(1):276-89. DOI: 10.1210/endo.142.1.7916. View

Gordon M, Margolin K, Talpaz M, Sledge Jr G, Holmgren E, Benjamin R . Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001; 19(3):843-50. DOI: 10.1200/JCO.2001.19.3.843. View

Bjorkman S, Shapiro A, Berntorp E . Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia. 2001; 7(2):133-9. DOI: 10.1046/j.1365-2516.2001.00465.x. View

10.

Kovarik J, Pescovitz M, Sollinger H, Kaplan B, Legendre C, Salmela K . Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. Clin Transplant. 2001; 15(2):123-30. DOI: 10.1034/j.1399-0012.2001.150208.x. View

11.

Cornillie F, Shealy D, DHaens G, Geboes K, Van Assche G, Ceuppens J . Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther. 2001; 15(4):463-73. DOI: 10.1046/j.1365-2036.2001.00956.x. View

12.

Dowell J, Korth-Bradley J, Liu H, King S, Berger M . Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol. 2001; 41(11):1206-14. DOI: 10.1177/00912700122012751. View

13.

Schulman E . Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med. 2001; 164(8 Pt 2):S6-11. DOI: 10.1164/ajrccm.164.supplement_1.2103025. View

14.

Kovarik J, Gridelli B, Martin S, Rodeck B, Melter M, Dunn S . Basiliximab in pediatric liver transplantation: a pharmacokinetic-derived dosing algorithm. Pediatr Transplant. 2002; 6(3):224-30. DOI: 10.1034/j.1399-3046.2002.01086.x. View

15.

St Clair E, Wagner C, Fasanmade A, Wang B, Schaible T, Kavanaugh A . The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002; 46(6):1451-9. DOI: 10.1002/art.10302. View

16.

Eppler S, Combs D, Henry T, Lopez J, Ellis S, Yi J . A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther. 2002; 72(1):20-32. DOI: 10.1067/mcp.2002.126179. View

17.

Church J, Cunningham C, Hughes M, Palumbo P, Mofenson L, Delora P . Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr Infect Dis J. 2002; 21(7):653-9. DOI: 10.1097/00006454-200207000-00010. View

18.

Kovarik J, Offner G, Broyer M, Niaudet P, Loirat C, Mentser M . A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations. Transplantation. 2002; 74(7):966-71. DOI: 10.1097/00007890-200210150-00011. View

19.

Lerner G, Kale A, Warady B, Jabs K, Bunchman T, Heatherington A . Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatr Nephrol. 2002; 17(11):933-7. DOI: 10.1007/s00467-002-0932-0. View

20.

Vieira Pinheiro J, Lanversa C, Wurthwein G, Beier R, Casimiro da Palma J, von Stackelberg A . Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Leuk Lymphoma. 2002; 43(10):1911-20. DOI: 10.1080/1042819021000015853. View